Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-06-04
2009-06-23
Naff, David M (Department: 1657)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S002600, C424S489000, C435S004000, C435S174000
Reexamination Certificate
active
07550441
ABSTRACT:
The present invention relates to a conjugate that includes a nucleic acid ligand bound to a controlled release polymer system, a pharmaceutical composition that contains the conjugate, and methods of treatment using the conjugate. The controlled release polymer system includes an agent such as a therapeutic, diagnostic, prognostic, or prophylactic agent. The nucleic acid ligand that is bound to the controlled release polymer system, binds selectively to a target, such as a cell surface antigen, and thereby delivers the controlled release polymer system to the target.
REFERENCES:
patent: 4458066 (1984-07-01), Caruthers et al.
patent: 5459015 (1995-10-01), Janjic et al.
patent: 5731144 (1998-03-01), Toothman et al.
patent: 5766853 (1998-06-01), Parma et al.
patent: 5846713 (1998-12-01), Pagratis et al.
patent: 5869641 (1999-02-01), Jayasena et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 6004534 (1999-12-01), Langer et al.
patent: 6140490 (2000-10-01), Biesecker et al.
patent: 6207649 (2001-03-01), Weis et al.
patent: 6331394 (2001-12-01), Ruckman et al.
patent: 6379699 (2002-04-01), Virtanen et al.
patent: 6409990 (2002-06-01), Vera
patent: 6670127 (2003-12-01), Evans
patent: 6916490 (2005-07-01), Garver et al.
patent: 7029897 (2006-04-01), Yue et al.
patent: 7312325 (2007-12-01), Sullenger et al.
patent: WO 01/09156 (2001-02-01), None
patent: WO 01/09157 (2001-02-01), None
*Biesecker, et al., “Derivation of RNA Aptamer Inhibitors of Human Complement C5”,Immunopharmacology, 42: 219-230, 1999.
*Bless, et al., “Protective Effects of an Aptamer Inhibitor of Neutrophil Elastase in Lung Inflammatory Injury”,Current Biology, 7: 877-880, 1997.
*Blank, et al., “Systematic Evolution of a DNA Aptamer Binding to Rat Brain Tumor Microvessels”,The Journal of Biological Chemistry, 276(19): 16464-16468, 2001.
*Bock, et al., “Selection of Single-Stranded DNA Molecules that Bind and Inhibit Human Thrombin”,Nature, 355(6360):564-566, 1992.
*Bridonneau, et al., “High-Affinity Aptamers Selectively Inhibit Human Nonpancreatic Secretory Phospholipase A2 (hnps-PLA2)”,Journal of Medicinal Chemistry, 41: 778-786, 1998.
*Davis, et al., “Staining of Cell Surface Human CD4 with 2′-F-Pyrimidine-Containing RNA Aptamers for Flow Cytometry”,Nucleic Acids Research, 26: 3915-3924, 1998.
*Dougan, et al., “Extending the Lifetime of Anticoagulant Oligodeoxynucleotide Aptamers in Blood”,Nucl. Med. Bio, 27(3): 289-297, 2000.
*Drolet, et al., Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor of Rhesus Monkey's,Pharmaceutical Research, 17(12): 1503-1510, 2000.
*Eyetech Study Group, Preclinical and Phase 1A Clinical Evaluation of an Anti-VEGF Pegylated Aptamer (EYE001) for the Treatment of Exudative Age-Related Macular Degeneration,Retina, 22: 143-152, 2000.
*Famulok, et al., “Aptamers as Tools in Molecular Biology and Immunology”,Microbiol. Immunol. 243: 123-136, 1999.
*Floege, et al., “Novel Approach to Specific Growth Factor Inhibition in Vivo: Antagonism of Platelet-Derived Growth Factor in Glomerulonephritis by Aptamers”,American Journal of Pathology, 154: 169-179, 1999.
*Gold, et al., “From Oligonucleotide Shapes to Genomic SELEX: Novel Biological Regulatory Loops”,Proc. Natl. Acad. Sci. USA, 94: 59-64, 1997.
*Green, et al., “Nuclease-Resistant Nucleic Acid Ligands to Vascular Permeability Factor/Vascular Edothelial Growth Factor”,Chem Biol., 2(10): 683-695, 1995.
*Green, et al., “Inhibitory DNA Ligands to Platelet-Derived Growth Factor B-Chain”,Biochemistry, 35: 14413-14424, 1996.
*Griffin, et al., “In Vivo Anticoagulant Properties of a Novel Nucleotide-Based Thrombin Inhibitor and Demonstration of Regional Anticoagulation in Extracorporeal Circuits”,Blood, 81(12): 3271-3276, 1993.
*Hicke, et al., “Escort Aptamers: A Delivery Service for Diagnosis and Therapy”,The Journal of Clinical Investigation, 106(8): 923-928, 2000.
*Hicke, et al., “DNA Aptamers Block L-Selectin Function in Vivo, Inhibition of Human Lymphocyte Trafficking in SCID Mice”,Journal of Clinical Investigation, 98: 2688-2692, 1996.
*Jayasena, S., “Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics”,Clinical Chemistry, 45(9): 1628-1650, 1999.
*Jellinek, et al., “Inhibition of Receptor Binding by High Affinity RNA Ligands to Vascular Endothelial Growth Factor”,Biochemistry, 33: 10450-10456, 1994.
*Jellinek, et al., “Potent 2′-Amino-2′- Deoxypyrimidine RNA Inhibitors of Basic Fibroblast Growth Factor”,Biochemistry, 36:11363-11372, 1995.
*Jellinek, et al., “High Affinity RNA Ligands to Basic Fibroblast Growth Factor Inhibit Receptor Binding”,Proc. Natl. Acad. Sci. USA, 90: 11227-11231, 1993.
*Jenison, et al., “Oligonucleotide Inhibitors of P-Selectin-Dependent Neutrophil-Platelet Adhesion”,Antisense Nucleic Acid Drug Dev., 4: 265-279, 1998.
*Kopylov, et al., “Combinatorial Chemistry of Nucleic Acids: SELEX”,Molecular Biology, 34(6): 940-954, 2000.
*Kubik, et al., “Isolation and Characterization of 2′-Fluoro-2′-amino-, and 2′-Fluoro-/Amino-Modified RNA Ligands to Human IFN-Gamma That Inhibit Receptor Binding”,J. Immunology, 159: 259-267, 1997.
*Kubik, et al., “High-Affinity RNA Ligands to Human Alpha-Thrombin”,Nucleic Acids Research, 22: 2619-2626, 1994.
*Lee, et al., “A Novel Oligodeoxynucleotide Inhibitor of Thrombin. II. Pharmacokinetics in the Cynomolgus Monkey”,Pharm. Res. 12(12): 1943-1947, 1995.
*Leppanen, et al., “Intimal Hyperplasia Recurs After Removal of PDGF-AB and -BB Inhibition in the Rat Carotid Artery Injury Model”,Aterioscler, Thromb. Vasc. Biol., 20: E89-95, 2000.
*Li, et al., “A Novel Nucleotide-Based Thrombin Inhibitor Inhibits Clot-Bound Thrombin and Reduces Arterial Platelet Thrombus Formation”,Blood, 83(3): 677-682, 1994.
*Lupold, et al., “Identification and Characterization of Nuclease-Stabilized RNA Molecules that Bind Human Prostate Cancer Cels via the Prostate-Specific Membrane Antigen”,Cancer Research, 62: 4029-4033, 2002.
*Meyer, et al., “Targeting a Genetically Engineered Elastin-Like Polypeptide to Solid Tumors by Local Hyperthermia”,Cancer Research, 61: 1548-1554, 2001.
*O'Connell, et al., “Calcium-Dependent Oligonucleotide Antagonists Specific for L-Selectin”,Proc. Natl. Acad. Sci. USA, 93: 5883-5887, 1996.
*Osborne, et al., “Aptamers as Therapeutic and Diagnostic Reagents: Problems and Prospects”,Curr. Opin. Chem. Biol.1:5-9, 1997.
*Ostendorf, et al., “The Effects of PDGF Antagonism in Experimental Glomerulonephritis are Independent of the TGF-Beta System”,J. Amer. Soc. Nephrology, 13: 658-667, 2002.
*Ostendorf, et al., “VEGF165 Mediates Glomerular Endothelial Repair”,J. Clinical Invest. 104: 913-923, 1999.
*Ostendorf, et al., “Specific Antagonism of PDGF Prevents Renal Scarring in Experimental Glomerulonephritus”,J. Amer. Soc. Nephrology, 12: 909-918, 2001.
*Pagratis, et al., “Potent 2′-Amino-, and 2′-Fluoro-2′-Deoxyribonucleotide RNA Inhibitors of Keratinocyte Growth Factor”,Nature Biotechnology, 15: 68-73, 1997.
*Patel, et al., “Structure, Recognition and Discrimination in RNA Aptamer Complexes with Cofactors, Amino Acids, Drugs and Aminoglycoside Antibiotics”,Reviews in Molecular Biotechnology, 74: 39-60, 2000.
*Pieken, et al., “Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes”,Science, 253(5017): 314-317, 1991.
*Pietras, et al., “Inhibition of Platelet-Derived Growth Factor Receptors Reduces Interstitial Hypertension and Increases Transcapillary Transport in Tumors”,Cancer R
Farokhzad Omid C.
Jon Sangyong
Langer Robert S.
Lahive & Cockfield LLP
Massachusetts Institute of Technology
Naff David M
Trinque Brian C.
LandOfFree
Controlled release polymer nanoparticle containing bound... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled release polymer nanoparticle containing bound..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release polymer nanoparticle containing bound... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4144146